Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Incrocci L, et al. Among authors: krol s. Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339116 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: krol s. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: krol s. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.
Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
Wortel RC, Heemsbergen WD, Smeenk RJ, Witte MG, Krol SDG, Pos FJ, Incrocci L. Wortel RC, et al. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1243-1252. doi: 10.1016/j.ijrobp.2017.07.044. Epub 2017 Aug 3. Int J Radiat Oncol Biol Phys. 2017. PMID: 28943074 Clinical Trial.
In Reply to Güngör et al.
Heemsbergen WD, Wortel RC, Incrocci L, Smeenk RJ, Witte MG, Pos FJ, Krol S. Heemsbergen WD, et al. Among authors: krol s. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1291-1292. doi: 10.1016/j.ijrobp.2017.12.284. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722665 No abstract available.
Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet.
Haas RL, Walraven I, Lecointe-Artzner E, Scholten AN, van Houdt WJ, Griffin AM, Ferguson PC, Miah AB, Zaidi S, DeLaney TF, Chen YL, Spalek M, Krol SDG, Moeri-Schimmel RG, van de Sande MAJ, Sangalli C, Stacchiotti S. Haas RL, et al. Among authors: krol sdg. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1226-1233. doi: 10.1016/j.ijrobp.2018.04.024. Epub 2018 Apr 17. Int J Radiat Oncol Biol Phys. 2018. PMID: 29859795
A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma.
van Meekeren M, Bovee JVMG, van Coevorden F, van Houdt W, Schrage Y, Koenen AM, Miah AB, Zaidi S, Hayes AJ, Thway K, Krol S, Fiocco M, Gelderblom H, Steeghs N, Haas RL. van Meekeren M, et al. Among authors: krol s. Acta Oncol. 2021 Dec;60(12):1557-1564. doi: 10.1080/0284186X.2021.1971294. Epub 2021 Sep 23. Acta Oncol. 2021. PMID: 34554030 Clinical Trial.
Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors.
Daniëls LA, Krol SD, de Graaf MA, Scholte AJ, van 't Veer MB, Putter H, de Roos A, Schalij MJ, van de Poll-Franse LV, Creutzberg CL. Daniëls LA, et al. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):164-71. doi: 10.1016/j.ijrobp.2014.05.038. Int J Radiat Oncol Biol Phys. 2014. PMID: 25195991 Clinical Trial.
Primary sarcoma of the heart: case report and literature review.
Moeri-Schimmel R, Pras E, Desar I, Krol S, Braam P. Moeri-Schimmel R, et al. Among authors: krol s. J Cardiothorac Surg. 2020 May 19;15(1):104. doi: 10.1186/s13019-020-01157-4. J Cardiothorac Surg. 2020. PMID: 32430055 Free PMC article. Review.
The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting.
Hagenmaier HSF, van Beeck AGK, Haas RL, van Praag VM, van Bodegom-Vos L, van der Hage JA, Krol S, Speetjens FM, Cleven AHG, Navas A, Kroon HM, Moeri-Schimmel RG, Leyerzapf NAC, van de Sande MAJ. Hagenmaier HSF, et al. Among authors: krol s. Sarcoma. 2021 Oct 21;2021:8851354. doi: 10.1155/2021/8851354. eCollection 2021. Sarcoma. 2021. PMID: 34720664 Free PMC article.
160 results